Expert Company devoted to Hematological Cancers

- **Our Mission:** Provide Efficient Treatment Solutions for Patients with Precision Medicine Approaches.
- **Our Strengths:** >20 Years Expertise in Multiple Myeloma, Unique Cellular Models, Patented Methodologies to the Identification of Predictive Biomarkers, and Customized Services.

**OUR MODELS**

**Panel of Unique Hematological Cancer Cell Lines**

- **Multiple Myeloma (MM) (40 cell lines):**
  - Representative of the Heterogeneity of MM Disease\(^1\)A.
  - Characterized by RNAseq, Exome seq, ChiPseq, SNP...
  - Profile of Response to 20 Molecules: IC50s.
  - Fully Characterized Panel of Treatments Resistant Cell Lines.
- **Diffuse Large B-Cell Lymphoma (DLBCL) (20 cell lines)**
- **Acute Myeloid Leukemia (AML) (10 cell lines)**

**Collection of Primary Cells from Patients**

- **MM samples**
- **All Hematological Malignancies**

**Unique in vitro Model of Human Plasma Cell Differentiation**

- **Multi Step Culture**\(^2,3,4\) Characterized (Memory B cells, Pre-Plasmablasts, Plasmablasts, Plasma cell, Long lived Plasma cell).
- **Drug Effect in Normal Plasma Cell Generation**\(^5\).

**Development of Predictive Biomarkers**

1. *In vitro* Treatment of Cell Lines. **Published**\(^6,7,8,9,10,11\) **And Patented**\(^B,C,D,E,F,G,H,I,J\).
2. RNAseq and Analyzis of Deregulated Genes.
3. Integration of Genomic and Clinical Data.
4. *In vitro* Biomarker Validation using Primary Cells.


OUR SERVICES

Find and Validate New Therapeutic Targets

- Analyze of your Targets Expression
  - Genomic Analyzes in Different Cohorts of Patients with Hematological Malignancies (Genomic and Clinical Data).
  - Analysis of the Prognostic Value of your targets (Survival Analysis).
  - Validation at the Protein Level using Flow Cytometry.

In vitro Cytotoxicity Studies

- Drug Screening
- In vitro Cell Growth Inhibition (IC50).
- Cell Cycle, Apoptosis, Clonogenic Assays.
- Synergistic Drug Combinations.
- Effect on Drug Resistant Cell Lines.
- Correlation of the Drug Response with Mutations and Gene Expression Profiling.

In Hematological Cell Lines

- In vitro Viability of Primary Tumor Cells co-cultured with their Bone Marrow Microenvironment.
- Flow Cytometry Assays to Investigate NK mediated Lysis of your Antibody.

In Primary Samples of Patients with Hematological Malignancies

- Effect in Normal Plasma Cells and in Different Stages (pre-Plasmablasts, Plasmablasts, Plasma Cells).

Biomarkers

- RNAseq and Gene Expression Profiling.
- Integration of Genomic and Clinical Data from Patients Cohorts.
- Identification of Biomarkers.
- In vitro Validation using Primary Samples from Patients.

Diag2Tec, Cap Omega, Rond Point Benjamin Franklin CS39521 34960 Montpellier Cedex 2 FRANCE

contact@diag2tec.com www.diag2tec.com